Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8FX9H
|
|||
| Drug Name |
PBFT02
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Frontotemporal dementia [ICD-11: 6D83] | Phase 1/2 | [1] | |
| Company |
Passage Bio
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Progranulin (PGRN) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04747431) A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the Cisterna Magna of Adult Subjects With Frontotemporal Dementia and Mutations in the Progranulin Gene. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Passage Bio | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.